Mark Cuban Cost Plus Drug Company

What Mark Cuban Cost Plus Drug Company does

Mark Cuban Cost Plus Drug Company (MCCPDC), operating as a Public Benefit Corporation headquartered in Dallas, Texas, is a direct-to-consumer mail-order pharmacy built around a transparent cost-plus pricing model. The company sells more than 2,500 generic medications at manufacturer acquisition cost plus a 15% markup and a $3-$5 dispensing fee, publicly disclosing manufacturing costs and bypassing pharmacy benefit manager (PBM) spread pricing. Since launching in January 2022, MCCPDC has grown to over 2 million members and serves patients in all 50 U.S. states through URAC-accredited pharmacy facilities. The platform's pricing transparency has been cited by academic research as offering 40-99% savings versus retail pharmacy prices and potential Medicare Part D savings of $8.6 billion annually on generics alone.

The company's product surface has expanded well beyond the original consumer pharmacy. Core offerings now include the Cost Plus Drugs consumer platform, the Cost Plus Marketplace for Businesses (B2B procurement integrated with GraphiteRx and Bluesight for hospital systems serving 40 million+ patients annually), the SwiftyRx digital pharmacy platform with AI-driven prescription verification and insurance benefit checks, and a Dallas-based $11 million fill-finish manufacturing facility producing sterile injectables including carboplatin. The company has entered branded drugs via the BMS-Pfizer Eliquis partnership at $345 per 30-day supply, biosimilars via the launch of Starjemza (a Stelara biosimilar at approximately 98% below originator list price), and GLP-1 obesity therapeutics through the Eli Lilly Employer Connect platform offering Zepbound at $449. Distribution runs through direct e-commerce, employer benefit partnerships with Humana's CenterWell Pharmacy, SmithRx, WellDyne, and RxPreferred Benefits, federal channels via the TrumpRx portal, and retail grocery via Giant Eagle.

Revenue is generated primarily through per-prescription transaction fees (the 15% markup plus dispensing fee) and through employer/PBM channel partnerships. The company is privately held by founder Mark Cuban, structured as a Public Benefit Corporation, with no disclosed external venture capital. Strategic alliances in 2025-2026 include collaborations with Alchem Laboratories for AI/ML-based manufacturing of 86 essential medicines and the federal Equip-A-Pharma initiative. The company is positioned as a structural disruptor of the U.S. pharmaceutical distribution chain, with brand strength anchored by Mark Cuban's personal media presence and bipartisan political visibility.

Name

Mark Cuban Cost Plus Drug Company

Legal name

Mark Cuban Cost Plus Drug Company, PBC

Website

https://costplusdrugs.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

51–100 employees

Short description

Mark Cuban Cost Plus Drug Company is a Dallas-based, Public Benefit Corporation operating a direct-to-consumer mail-order pharmacy that sells 2,500-plus generic medications at manufacturer cost plus 15% markup and a $3-5 dispensing fee, serving 2 million members across all 50 U.S. states with documented 40-99% savings versus retail prices.

Ownership category

akta.pro rank

Product category

Online Pharmacy

NAICS

Pharmacies and Drug Retailers (456110), Pharmacies and Drug Retailers (45611), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Retail-Drug Stores And Proprietary Stores (5912), Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Discount Drugstores (Value-Focused Chain Pharmacies) (CRAEAHAA)

akta.pro secondary industries

Copay Assistance, Patient Support & Affordability Programs (HLAEAKAI), Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Pharmacy Benefit/Channel Services (PSAO, 340B Admin, Chargebacks/Rebates Ops) (CRAOAHAK)

Keywords

• Online pharmacy services
• Generic drug pricing
• Mail-order prescriptions
• Pharmacy benefit management
• Cost-plus pharmaceuticals

Headquarters

HQ city

Dallas

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Supply Chain, Operations, Infrastructure, Technology or R&D, Personnel, Marketing or Sales

Revenue model

1. Pharmacy Dispensing Fees: The company generates revenue through a transparent cost-plus pricing model: acquisition cost plus 15% markup plus a $3-5 dispensing fee. Patients pay for medications directly without insurance involvement for most generic prescriptions.
2. Employer Benefit Solutions: Revenue generated through employer partnerships via SwiftyRx platform and CenterWell collaboration, providing prescription cost management solutions to employer groups facing rising healthcare costs

Pricing tiers

Go-to-market motion4 records

Distribution channels7 records

Marketing channels6 records

Core offering

Mark Cuban Cost Plus Drug Company operates a direct-to-consumer online pharmacy (costplusdrugs.com) that dispenses more than 2,500 generic medications at a transparent cost-plus price equal to manufacturer acquisition cost plus a 15% markup plus a $3–$5 pharmacy dispensing fee, with mail delivery to all 50 U.S. states. It has expanded into a B2B Cost Plus Marketplace for Businesses, employer benefit solutions via the SwiftyRx AI platform (partnered with Humana CenterWell), branded/biosimilar offerings (Eliquis, Starjemza), and an $11 million Dallas manufacturing facility producing sterile injectables.

Product overview

Mark Cuban Cost Plus Drug Company operates as a direct-to-consumer pharmacy platform with a transparent cost-plus pricing model (manufacturer cost plus 15% markup plus $3-5 dispensing fee). The core offering is the consumer platform at costplusdrugs.com, which has grown to over 2,500 generic medications serving 2 million members with up to 80% savings versus retail pharmacies. The product portfolio includes the consumer platform, Cost Plus Marketplace for Businesses (B2B procurement), SwiftyRx (AI-powered employer prescription solutions), Dallas manufacturing facility for sterile injectables, and participation in federal initiatives like TrumpRx. The company also offers specialty medications including biosimilars like Starjemza and branded drugs like Eliquis through partnerships with pharmaceutical manufacturers. Key differentiators include URAC-accredited facilities, AI-powered prescription verification through SwiftyRx, and partnerships with CenterWell Pharmacy, GraphiteRx, and Medchat.ai.

Differentiator

Problem solved

Functional benefit

Brands

• SwiftyRx: AI-powered digital pharmacy platform that uses AI to verify prescriptions and check insurance benefits, integrated into employer prescription solutions.

Products and services

• Cost Plus Drugs Online Pharmacy
• Cost Plus Marketplace for Businesses
• SwiftyRx Digital Pharmacy Platform
• Starjemza (ustekinumab-hmny) Biosimilar
• Eliquis (apixaban) Direct Offering
• Employer Prescription Solutions (with Humana CenterWell)
• Zepbound (tirzepatide) Direct Distribution via Lilly Employer Connect

Quantifiable outcome

• Patients save up to 85% on out-of-pocket costs when buying directly from MCCPDC for prescriptions with copayments exceeding $15
• +4 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability7 records

Feature4 records

Partnerships

16 partnerships are on record, tiered core, minor and flagship.

• SmithRxcoreChannel Partner/ Reseller/ Distributor · 9 June 2026MCCPDC integrated into SmithRx's best-in-class partner ecosystem for GLP-1 employer programs. The ecosystem leverages manufacturer-approved cash-pay pricing and transparent 100% pass-through PBM model, helping employers deliver sustainable GLP-1 coverage at scale with up to 70% cost savings.
• Elevance HealthminorChannel Partner/ Reseller/ Distributor · 28 May 2026Integration of MCCPDC into Cost Plus Marketplace for businesses as Elevance Health expands access to affordable medications for employer groups and health plan members.
• TrumpRxcoreGTM or Marketing Partner · 23 May 2026MCCPDC supplies 559 generic medications to the TrumpRx federal prescription drug pricing portal. Mark Cuban appeared at the White House alongside President Trump to announce the partnership, describing it as a 'special partnership' and noting bipartisan support for cheaper drugs across political lines.
• PaytientminorGTM or Marketing Partner · 7 May 2026Partnership with healthcare affordability and payment solutions company. 72% of Paytient members report increased employer retention and 96% report reduced financial stress when using the platform.
• Humana CenterWell PharmacycoreStrategic or Co-development Partner · 27 April 2026Deepened partnership to develop end-to-end employer prescription solutions combining Cost Plus Drugs' low-cost transparent pricing and SwiftyRx technology with CenterWell's distribution capabilities. The collaboration aims to streamline patient onboarding, automate benefit checks, reduce medication costs for employers, and provide home delivery pharmacy services to Humana's eligible workforce enrolled in the Associate Benefit Plan.
• Bristol Myers Squibb-Pfizer AllianceflagshipGTM or Marketing Partner · 24 April 2026Collaboration to make Eliquis (apixaban), the nation's most prescribed oral blood thinner, available on CostPlusDrugs.com starting April 27, 2026. Cash-paying patients can purchase a 30-day supply for $345, providing a reduced-cost direct purchasing option compared to standard pharmacy pricing.
• RxPreferred BenefitsminorChannel Partner/ Reseller/ Distributor · 14 April 2026Collaboration with RxPreferred's affiliate pharmacy network as part of their transparent business model featuring 100% pass-through pricing and no spread pricing for employer and health system clients.
• Eli LillycoreGTM or Marketing Partner · 5 March 2026Partner through Lilly Employer Connect platform enabling employers to provide Zepbound (tirzepatide) at $449 across all doses through MCCPDC's pharmacy network. Targets the gap where nearly half of commercially insured Americans lack obesity medication coverage.
• Alchem LaboratoriescoreStrategic or Co-development Partner · 27 January 2026Strategic alliance to develop essential medicine therapeutics and improve supply chain resiliency through automated manufacturing using AI and machine learning. Initial focus on lidocaine and diltiazem production, with collaboration to supply 86 essential medicines and medical countermeasures including critical care drugs and antimicrobials.
• GraphiteRxcoreTechnology or Integration · 4 December 2025Expanded partnership to enhance Cost Plus Marketplace for businesses, improving access to affordable medications for healthcare providers. Collaboration supports supply chain efficiency and serves over 40 million patients annually.
• Johnson & JohnsonflagshipGTM or Marketing Partner · 6 November 2025MCCPDC launched Starjemza (ustekinumab-hmny), a biosimilar to J&J's Stelara, priced at approximately $360 per syringe (~$1,400-$2,200/year) compared to Stelara's ~$29,000/syringe list price - a 98% price reduction.
• Genentech/RocheminorChannel Partner/ Reseller/ Distributor · 16 October 2025Genentech's direct-to-patient program for Xofluza flu treatment partnered with MCCPDC and other pharmacies including Alto Pharmacy and Amazon Pharmacy, offering $50 cash pay option and same-day home delivery.
• Know WellnessminorGTM or Marketing Partner · 23 September 2025Partnership to offer affordable prescriptions through Know Wellness' holistic health platform featuring AI-powered facial scans, at-home biomarker testing, and personalized supplements for accessible data-driven preventive care.
• Giant EagleminorChannel Partner/ Reseller/ Distributor · 6 August 2025Partnership with grocery chain Giant Eagle to lower prescription drug prices by offering transparent pricing model in five states, expanding consumer access to affordable medications through retail locations.
• WellDyneminorChannel Partner/ Reseller/ Distributor · 22 May 2025Integration of MCCPDC into WellDyne's PBM routing strategy alongside Waltz Health's AI-powered platform, surfacing real-time alerts helping members find affordable medication options through automated claims adjudication.
• Morris & DicksonminorChannel Partner/ Reseller/ Distributor · 16 April 2025Partnership with specialty pharmaceutical distributor Morris & Dickson to improve access to injectable medications and supply chain efficiency. Aims to ensure steady availability of rare drugs and lower costs for healthcare providers.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• GoodRx: Publicly traded prescription drug price comparison and discount platform offering coupons and mail-order pharmacy (through Hey Doctor/Kroger partnership). Competes on the same uninsured/underinsured consumer segment with a coupon-driven rather than cost-plus model.
• Amazon Pharmacy: Amazon's online mail-order pharmacy offering transparent pricing on generics and integration with Prime for home delivery. Direct competitor to MCCPDC's DTC mail-order model with substantially larger capital base and existing customer reach.
• Ro: DTC telehealth platform with vertically integrated pharmacy offering branded and generic medications, including GLP-1 distribution. Operates a similar transparent pricing model and competes for the same high-deductible consumer segment.
• Capsule Pharmacy: Digital-first pharmacy offering free same-day delivery, transparent pricing, and personalized pharmacist support. Directly comparable mail-order and DTC pharmacy model targeting urban insured/underinsured consumers.
• Alto Pharmacy: Digital pharmacy with same-day delivery and transparent pricing. Competes directly on the insured/underinsured consumer with free delivery and care coordination, recently named alongside MCCPDC as a Genentech Xofluza partner.
• Hims & Hers Health: DTC telehealth and pharmacy platform offering prescription medications directly to consumers. Operates a similar mail-order model with transparent pricing and has expanded aggressively into GLP-1 and specialty medications, overlapping with MCCPDC's employer/PBM channels.

Broad incumbents

• Express Scripts (Cigna): One of the three largest U.S. PBMs administering prescription benefits for large employer groups and health plans. The spread-pricing practices of Express Scripts (and peers) are what MCCPDC's transparency model is designed to expose and replace.
• CVS Caremark: Major PBM and retail pharmacy chain offering both physical and mail-order prescription fulfillment. Operates the incumbent model that MCCPDC's cost-plus pricing directly competes against, especially in employer benefits.
• Optum Rx (UnitedHealth Group): Largest U.S. PBM administering pharmacy benefits for tens of millions of members. Represents the incumbent model MCCPDC is structurally bypassing, but is a potential integration/partner channel given Smith's pass-through PBM evolution.

Emerging players

• RxPreferred Benefits: Transparent PBM offering 100% pass-through pricing to employer and health system clients. Direct partner in MCCPDC's ecosystem and a structural peer in the transparent PBM space targeting the same employer RFP opportunities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/costplusdrugs
• YouTubeyoutube.com/channel/UCGQn107w5vpKT7jfdjixg4g
• Facebookfacebook.com/costplusdrugs
• LinkedInlinkedin.com/company/costplusdrugs
• Instagraminstagram.com/costplusdrugs

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mark Cuban Cost Plus Drug Company